000			02153na a2200265 4500
003			H12O
005			20210625062802.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCiruelos Gil, Eva María _91082 _eOncología Médica
100			_aRodríguez Peralto, José Luis _91219 _eAnatomía Patológica
245	0	0	_aMouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes. _h[artículo]
260			_bPLoS ONE, _c2012
300			_a7(8):e42494.
500			_aFormato Vancouver: Dueñas M, Santos M, Aranda JF, Bielza C, Martínez-Cruz AB, Lorz C, et al. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One. 2012;7(8):e42494.
501			_aPMID: 22880004
504			_aContiene 70 referencias
520			_aMutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs. We previously showed the transcriptome of a p53-deficient mouse skin carcinoma model to be similar to those of human cancers with TP53 mutations and associated with poor clinical outcomes. This report shows that much of the 682-gene signature of this murine skin carcinoma transcriptome is also present in breast and lung cancer mouse models in which p53 is inhibited. Further, we report validated gene-expression-based tests for predicting the clinical outcome of human breast and lung adenocarcinoma. It was found that human patients with cancer could be stratified based on the similarity of their transcriptome with the mouse skin carcinoma 682-gene signature. The results also provide new targets for the treatment of p53-defective tumours.
710			_9303 _aServicio de Oncología Médica
710			_9330 _aServicio de Anatomía Patológica
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413665/ _yAcceso libre
942			_n0 _2ddc _cART
999			_c5703 _d5703